Using personalized medicine to avoid resistance to leukemia treatment

T-cell acute lymphoblastic leukemia is an aggressive cancer type that mostly affects children. The standard treatment is chemotherapy, but about one in four patients do not respond or develop resistance to this. Now, researchers from the University of Copenhagen have found a combination treatment that could benefit these patients and increase the survival rate.